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Available online at www.sciencedirect.comThe innate lymphoid cell (ILC) family has recently expanded
with the discovery of type-2 innate lymphoid cells (ILC2). These
cells arise from lymphoid progenitors in the bone marrow and,
under the control of the transcriptional regulators RORa and
Gata3, they mature to give rise to IL-5, IL-9 and IL-13 producing
ILC2. These cells are critical components of the innate immune
response to parasitic worm infections and have also been
implicated in the pathogenesis of asthma and allergy. Recent
advances in our understanding of the molecular regulation of
ILC2 development and function now present the opportunity to
develop new genetic models to assess ILC2 immune function
and to investigate possible therapeutic interventions.
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Introduction
The past few years have witnessed a change in our
perception of immune regulation; shifting from a view
that holds T cells at the centre of immune orchestration to
one that encompasses the significant contribution made
by the innate immune system and particularly the newly
identified cytokine-producing innate lymphoid cells
(ILCs). The ILC family comprises a group of cytokine-
competent cells with lymphoid morphology, which lack
re-arranged antigen-specific receptors. Importantly, these
cells provide a potent innate source of cytokines (that
were previously primarily associated with T helper cells),
and play diverse roles in lymphoid tissue formation,
immunity, inflammation and tissue remodelling [1]. Con-
sistent with their emerging roles in immune surveillance
and the initiation of immune responses, ILCs are particu-
larly prevalent at mucosal surfaces and respond to factors
derived from the epithelium, which might indicate stress
or microbial breach. NK cells and LTi cells represent the
prototypic members of the ILC family, which has grown
recently to include subsets regulated by the transcription
Open access under CC BY license.Current Opinion in Immunology 2013, 25:148–155 factors RORgt (ILC3), or RORa and Gata3 (ILC2) [2,3].
ILC3 secrete predominantly IL-22 and IL-17 and have
been implicated in the maintenance of intestinal barrier
function and immune homeostasis [1]. ILC2 on the other
hand, which form the focus of this review, provide an
innate source of type-2 cytokines and are critical for the
initiation of anti-helminthic and allergic immune
responses. Here we summarise the functional significance
of ILC2 in immunity and homeostasis and review the
recent advances in our understanding of the molecular
mechanisms that govern ILC2 development.
ILC2 — a definition
ILC2 were first reported in Rag2/ mice as an IL-25-
responsive, non-B non-T cell source of type-2 cytokines
[4,5] and were subsequently found to provide a critical
source of IL-13 in anti-helminthic immune responses
[6]. More recently, these cells have been characterised
extensively and the names originally ascribed to them by
the discovering laboratories — nuocytes [7], natural
helper cells (NHC) [8] and innate helper 2 cells (Ih2)
[9] — have been assimilated under the term ‘group 2
innate lymphoid cells’, or ILC2 [2]. ILC2 are defined
by their ability to produce the type-2 signature cytokines
IL-5, IL-9 and IL-13, but they also produce IL-6, IL-10,
GM-CSF and small quantities of IL-4. Phenotypically,
ILC2 are demarcated by the absence of conventional
lineage markers (for B, T, myeloid and erythroid cells),
in combination with the expression of ICOS, Sca1, IL-
7Ra, CD25 and receptors for the cytokines, IL-25
(IL17BR) and IL-33 (T1/ST2). ILC2 reside in fat-associ-
ated lymphoid clusters (FALC), lymph nodes (including
mesenteric (MLN) and mediastinal), spleen, liver,
intestines and the airways, and originate from common
lymphoid precursors (CLPs) in the bone marrow
[10,11]. ILC2 can be generated from CLPs in vitro
on Delta-like ligand-expressing OP9 stromal cells in
the presence of IL-7 and IL-33 [10]. Whilst most of
the investigations of ILC2 biology have been conducted
in the mouse, similar populations have been identified in
human lung and intestinal tissues and, consistent with their
proposed roles in mediating type-2 immunity and inflam-
mation, these cells are found in elevated proportions in the
nasal polyps of patients with chronic rhinosinusitis
[12,13,14]. Human ILC2 are typically defined as line-
ageIL-7Ra+NKp44CD25+CD161+CRTH2+ [12].
ILC2 function
Intestinal parasitic worm clearance
Type-2 immune responses are not only required for the
efficient expulsion of helminthic parasites, but are also
implicated in the inflammatory processes that drivewww.sciencedirect.com
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immune responses, ILC2 serve as a critical early source
of IL-13, which is instrumental in driving the physiologi-
cal ‘weep and sweep’ processes such as goblet cell mucus
secretion and contraction of intestinal smooth muscle
which are required to effect worm expulsion
[7,8,9,15,16].
Nippostrongylus brasiliensis is a parasite of the rat intestine
that can be transmitted experimentally to mice. The
parasite’s life cycle includes a free-living and a parasitic
intestinal phase. Immuno-competent mice clear primary
infections within six to ten days with the generation of
protective type-2 immunity, whilst disruption of the IL-
13 pathway compromises parasite clearance [17,18]. Th2
cells were considered as an important source of type-2
cytokines in worm clearance, as SCID and Rag2/ mice
lacking T and B cells cannot expel N. brasiliensis unless
given administrations of IL-13 [19]. However, adoptive
transfer of il4/il13/ T cells into N. brasiliensis-infected
Rag2/ mice induced worm expulsion, suggesting that
type-2 cytokine production was not the essential effector
function of T cells in anti-helminth responses [20].
During analysis of IL-25-deficient mice, a novel cell that
was induced by N. brasiliensis infection was identified.
This cell was determined to be negative for many lineage
markers, but expressed cKit, Thy1.2, and high levels of
IL-13 and IL-5 [6]. Although this IL-25-responsive
NBNTcKit+IL-13+ cell correlated with N. brasiliensis
expulsion, it was unclear if this cell was responsible for
parasite immunity [6]. The generation of IL-13eGFP
reporter mice allowed identification of all the IL-13-
secreting cells evoked by N. brasiliensis infection and
showed that the majority of these cells were ILC2.
Adoptive transfer of wildtype, but not IL-13-deficient,
ILC2 into N. brasiliensis-infected il17br/il1rl1/ mice,
which are severely impaired in their ability to expel
worms, restored protective type-2 immunity. Indeed,
transferring wildtype ILC2 into IL-13-deficient mice
confirmed that IL-13 secretion from ILC2 alone was
sufficient to induce parasite expulsion. Since ILC2 failed
to undergo sustained expansion in helminth-infected
rag2/ mice T cells appear to play an important, but
as yet undefined, role in sustaining ILC2 responses.
Significantly gc/Rag2/ mice infected with N. brasi-
liensis also fail to expel N. brasiliensis until they are recon-
stituted with ILC2 resulting in the restoration of goblet
cell hyperplasia in the recipient mice.
Asthma, lung inflammation and airways hyperreactivity
Allergic asthma is a chronic inflammatory disease of the
airways arising as a consequence of inappropriate
immunological responses to environmental stimuli.
Asthma is characterised by airways hyper-reactivity,
mucus production, eosinophil and mast cell recruitment,
smooth muscle contraction and airway remodelling, all ofwww.sciencedirect.com which contribute to bronchoconstriction. Recent evi-
dence suggests that the type-2 immune response is
initiated by epithelial cell-derived cytokines such as
IL-25, IL-33 and TSLP (thymic stromal lymphopoietin)
(Figure 1).
Notably, IL-33 or IL-25 can initiate type-2 cytokine
production, accompanied by eosinophilic lung inflam-
mation and AHR, in Rag2/ mice, independently of
adaptive immunity [21,22]. The presence of IL-25-
responsive and IL-33-responsive ILC2 in the naı¨ve lung
[14,22,23] is consistent with ILC2 being important in
initiating type-2 responses in the airways. In fact, IL-13-
producing lung ILC2 were upregulated following intra-
nasal IL-25 or IL-33 administration, or during an oval-
bumin-driven model of allergic asthma [24], and adoptive
transfer of wildtype, but not IL-13-deficient, ILC2 was
sufficient to restore IL-25-induced AHR to otherwise
resistant IL-13-deficient mice.
The fungal aeroallergen, Alternaria alternata [22] has also
been reported to induce ILC2 following the rapid
initiation of IL-33 production in the airways, even in
mice lacking B and T cells. ILC2 isolated from the lungs
of wildtype mice restored the Alternaria-induced AHR
response. Similarly, lung challenge with the glycolipid
antigen, a-galactosylceramide (a-GalCer) drove IL-33
production, which appeared to be critical for the induc-
tion of IL-13-secreting ILC2. However, NKT cells also
produced IL-13 in this model, and were as efficient as
ILC2 in restoring AHR when adoptively transferred to
Il13/ hosts.
Asthma exacerbations can be triggered by viral respiratory
tract infections, and a mouse model of rhinovirus infec-
tion has revealed that viral infection correlated with
elevated levels of the type-2 cytokines IL-13 and IL-4
and was associated with lung inflammation and AHR [25].
Recent reports have highlighted roles for ILC2 in exper-
imental models of influenza virus infection [14,26]. In
response influenza subtype H3N1 infection, AHR was
critically dependent on IL-13 and adoptive transfer of
ILC2 was capable of restoring AHR to IL-13-deficient
recipients. Consistent with a role for ILC2, influenza
infection-induced AHR occurred independently of the
adaptive immune response, but depended on the IL-33-
ST2 signalling pathway, similar to allergic asthma. These
results suggest that ILC2 may be responsible for eliciting
asthma exacerbation in response to influenza infection
[26].
A role for ILC2 in promoting lung repair after influenza
infection has also been proposed [14]. Depletion of ILC
in Rag1/ mice, using an anti-CD90.2 antibody, high-
lighted a role for ILCs in maintaining epithelial integrity
and lung function following H1N1-infected mice, and
lung repair was restored by the adoptive transfer ofCurrent Opinion in Immunology 2013, 25:148–155
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ILC2 as instigators of type-2 immunity. ILC2 play critical roles in immune responses towards helminthic parasites, viruses and allergens. In response to
cytokines such as IL-25, IL-33 and TSLP, which serve as ‘distress’ signals from the epithelium, ILC produce type-2 cytokines to activate type-2
effector pathways.CD90.1+linST2+ cells. Notably, administration of
recombinant IL-13 did not recapitulate this result and
gene expression profiling identified a number of genes
associated with tissue remodelling and wound healing
including amphiregulin, a member of the epidermal
growth factor family. Administration of amphiregulin
was sufficient to restore lung function.
ILCs that secrete IL-22 have been identified recently
in the lungs of mice during a model of experimental
allergic asthma [27], and experiments using Il22/mice
demonstrated that IL-22 plays a protective role in limit-
ing AHR and airway inflammation. Consistent with
these findings, the AHR response could be exacerbated
by using an anti-IL-22 antibody, or ameliorated by
the administration of exogenous IL-22. Human ILC2Current Opinion in Immunology 2013, 25:148–155 (LinCD127+ST2+CD161+CRTH2+) have been
reported in the lung parenchyma and bronchoalveolar
lavage and were also enriched in nasal polyps from
patients with chronic rhinosinusitis [12,14]. These cells
share a number of markers with mouse ILC2 and produce
IL-13 in response to IL-25 and IL-33, but did not
produce IL-17A or IL-22 and were negative for the
NKp44 receptor [12].
Transcriptional control of ILC2 development
Losing B and T potential
ILC2, similar to other branches of the ILC family, arise
from CLPs in the bone marrow and require the transcrip-
tional inhibitor Id2 for their development [8,10,11].
Id2 is a member of the basic helix-loop-helix (bHLH)
family of transcriptional regulators and serves to inhibitwww.sciencedirect.com
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Transcriptional control of ILC2 ontogeny. ILC2 development, similar to that of other ILC family members, requires the transcriptional regulator Id2 and
potentially Notch receptor signalling. Subsequent differentiation from a committed ILC progenitor (proILC) is governed by the expression of ILC
lineage-specific transcription factors. ILC2 development, via an ILC2 precursor (preILC2), is directed by the transcription factors RORa and Gata3. The
specific roles of these transcription factors throughout ILC2 ontogeny in the bone marrow and peripheral tissues, and in the generation of activated
cytokine-producing cells, are yet to be fully elucidated.the transcription activity of E proteins, namely E12, E47,
HEB and E2-2 [28]. These proteins are implicated at
various stages in the differentiation of B and T cells and it
is likely that suppression of the E proteins, and therefore
these alternative cell fates, represents a crucial step in the
ILC developmental pathway. In fact, deletion of E2A is
sufficient to restore the generation of conventional NK
cells in Id2-deficient mice [29].
Given the apparent importance of suppressing non-ILC
developmental pathways, it is noteworthy to consider the
role of Notch signalling in ILC development. Notch
signalling is required to block B cell potential during T
cell development [30], and subsequently provides a
means to repress NK cell differentiation [31]. The timing
and duration of Notch signals therefore provide critical
instructions to modulate lymphoid differentiation.
Recent studies suggest that Notch signalling pathways
are instructive in the development of LTi, ILC3 and
certain NK cell subsets [10,32–35]. In the case of ILC2,
Notch signalling is required for the generation of these
cells from CLPs in vitro, although the necessity of this
pathway in vivo has yet to be ascertained. Nevertheless,
only a transient Notch signal is required in CLP cultures,
consistent with a role for this pathway in suppressing
alternative cell fates, rather than in instructing ILC2
differentiation per se [10].www.sciencedirect.com The shared requirement for Id2 by all ILC lineages
[8,36–38], and potentially for Notch signalling, suggests
a compelling hypothesis that invokes a common Id2+
precursor cell, which is directed toward particular ILC
phenotypes by the expression of lineage-specific tran-
scription factors (Figure 2) [1]. RORgt (encoded by Rorc)
has been identified as a key regulator of ILC3 cells [38–
41], whilst E4BP4 (NF-IL3) is critical to the development
of NK cells [42,43]. Recently, RORa and Gata3 have
been identified as key determinants of ILC2 differen-
tiation and function, the specific roles of which will be
considered in the following sections [10,13,44,45].
Consistent with this ‘common precursor’ model for ILC
development, examination of LTi cell differentiation
suggests that this process is governed by the sequential
up-regulation of Notch, Id2 and RORgt [35], the early
phase of which is accompanied by the acquisition of a4b7
expression and a loss of B cell potential [32,35,46,47].
RORa
On the basis of gene expression data from ex vivo ILC2,
we have recently identified RORa as a regulator of ILC2
differentiation and function [10]. Using ‘staggerer’ mice,
which carry a spontaneous deletion within the Rora gene
[48], we have demonstrated that this transcription factor is
essential for ILC2 development [10], and this was
corroborated recently [44]. Whilst only modestCurrent Opinion in Immunology 2013, 25:148–155
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FALC of naı¨ve animals ([10,44] and JAW, unpub-
lished), expansion of the ILC2 population in response
to IL-25 injection, N. brasiliensis infection or intranasal
papain administration was severely impaired, and charac-
teristic type-2 immune responses failed to ensue
[10,44]. These results suggest critical roles for RORa
in at least two phases of ILC2 ontogeny; during differ-
entiation in the bone marrow and in the response to
immune challenge in peripheral tissues.
Regarding a role in ILC2 development, RORa-deficient
mice lack a population of ILC2-like cells in the bone
marrow (termed ‘iNH’), which display a robust capacity to
generate ILC2 upon adoptive transfer [44]. These cells
are defined by their expression of conventional ILC2
surface molecules, such as Sca-1, IL-7Ra, CD25 and
ST2, but have yet to initiate robust type-2 cytokine
expression and have reduced expression of CD69,
CXCR4 and CD122 compared to mature ILC2. This
ILC2 precursor population appears phenotypically
similar to the Gata3-dependent population identified
by Hoyler et al., which is discussed in the next section
[45].
A second potential role for RORa is in directing ILC2
proliferation and effector function. In fact, whilst ILC2-
like cells can be detected in the peripheral tissues
of RORa-deficient mice [10,44], these cells fail
to expand in response to triggering cytokines. At pre-
sent, it is unknown whether RORa-deficiency confers
only a proliferation defect, or whether ILC2 effector
function and cytokine capacity are also impaired. A
challenge for the future is therefore to establish
whether the ILC2-like cells that arise in RORa-
deficient mice are qualitatively equivalent to their wild
type counterparts.
Rora mRNA is broadly expressed amongst ILC popu-
lations [13,45] (albeit to a considerably higher degree
in ILC2), and it is intriguing that the effect of Rora
deletion is only apparent within the ILC2 subset. Indeed,
the other ILC subsets are present at normal frequency in
RORa-deficient mice [10,44]. More sophisticated
mouse models in which Rora can be deleted in specific
ILC lineages will be required to elucidate the specific
roles played by RORa in ILC2 development, and to
understand the mechanisms of redundancy that might
exist within other ILC lineages.
The identification of RORa as a critical transcription
factor in ILC2 development offers the possibility of
targeting this regulator to block ILC2 generation and
ameliorate allergic disease. The potential for this out-
come is supported by a report that RORa-deficient mice
fail to develop experimental allergic asthma [49]. ROR
inhibitors have been shown to be effective in suppressingCurrent Opinion in Immunology 2013, 25:148–155 EAE, driven by RORgt-expressing Th17 cells [50], and
their efficacy in targeting RORa during allergy and
asthma awaits investigation.
Gata3
Expression of Gata3 by ILC2 has been recognised by
several groups [8,9] and recently functional roles for
this transcription factor have been identified in the ILC2
lineage. Initially, Liang et al. identified a Gata3-expres-
sing ILC2 subset, which is induced during N. brasiliensis
infection and is competent to produce IL-13 [51]. Using
an Il13-driven Cre recombinase to delete loxP-flanked
Gata3 alleles, these authors demonstrated that although
Gata3 was dispensable for the survival of Gata3+IL-13+
ILC2, it was required for type-2 cytokine production.
More recently, Hoyler et al. have used a tamoxifen-
inducible Cre-loxP system, to delete Gata3 from Id2-
ERt2Cre expressing cells. Upon tamoxifen adminis-
tration, deletion of Gata3 resulted in the selective abla-
tion of ILC2 cells in vivo and resulted in their impaired
survival in culture. These studies suggest that, at least
before activation and IL-13 production, Gata3 is critical
for the maintenance of ILC2. Similarly, Gata3 is of
functional importance for human ILC2, and partial silen-
cing of Gata3 resulted in reduced responsiveness of ILC2
to IL-33 and TSLP [13]. Conversely, ectopic expres-
sion of Gata3 in a CRTH2–ILC population conferred
certain attributes of the ILC2 lineage,  including up-
regulation of CRTH2 and expression of the receptors
for IL-33 and TSLP, which in turn increased the pro-
pensity of transduced ILCs to produce type-2 cytokines
[13].
In addition to its expression in mature ILC2, Gata3
defines an ILC2-committed precursor population in the
bone marrow, similar to the population identified by
Halim et al. [44], which can be adoptively transferred
to alymphoid recipients to give rise to ILC2 in peripheral
tissues [45]. This lineage–Sca1+Id2+Gata3+ (or ‘LSIG’)
precursor generated only ILC2 upon transfer and could
not be induced to adopt alternative cell fates in vitro.
Deletion of Gata3 resulted in ablation of the LSIG
population, suggesting that it too requires Gata3 for its
generation or maintenance.
Of course Gata3 is also an essential component of CD4 T
cell development and the differentiation of Th2 cells
[52], indicating a conserved developmental programme
between Th2 and ILC2, and also the differentiation of
certain NK cell subsets [53,54]. By contrast, no such
function has been reported for RORa in Th2 or NK cell
differentiation, though a minor role exists for RORa as a
subordinate to RORgt in Th17 differentiation [55].
Clearly significant questions remain as to the molecular
events that regulate Gata3 and RORa in ILC2 in com-
parison to T cells, and the identity of their downstream
target genes.www.sciencedirect.com
Group 2 innate lymphoid cells Walker and McKenzie 153An ILC2 precursor (preILC2)
By virtue of their characteristic ILC2 surface marker
profile (e.g. Sca1, CD25 and ST2), ILC2-like cells have
been identified in the bone marrow by several groups
[7,44,45,56] though it has proven challenging to
determine whether these cells truly represent precursors
to the ILC2 lineage, or merely mature cells in an atypical
location. Both iNH and LSIG are poor producers of
cytokine and differ in their surface marker profile from
‘mature’ ILC2, for example LSIG retain a4b7 surface
expression and lack the lectin-like receptor KLRG1.
However, perhaps the most compelling evidence that
this population might represent a true lineage committed
precursor [44,45] is their ability to reconstitute the
ILC2 compartment of alymphoid mice 20–30 times more
efficiently than peripheral ILC2, without giving rise to
other related lineages. With the recent rationalisation of
ILC nomenclature we would suggest that these ILC2
precursors be referred to as preILC2.
Conclusions
Thus, RORa and Gata3 are both instrumental in ILC2
development and function and, whilst neither is restricted
to this lineage, the consequences to ILC development
appear specific to ILC2. However, the transcriptional
targets of these two factors remain to be ascertained
and it will be intriguing to determine whether they
overlap with those identified in T helper cell subsets.
Whilst evidence exists for a potential immature precursor
of ILC2, we still do not understand the extrinsic signals
and transcriptional changes required for the progressive
lineage restriction of CLPs to common Id2+ ILC pro-
genitors, and subsequently to immature precursors of the
individual ILC lineages. Elucidation of these molecular
pathways presents an exciting challenge for the future.
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